Profound Medical Inc. (PMI) is commercialising a unique, minimally-invasive approach for the treatment of prostate cancer.

Our technology combines the already proven clinical efficacy of ultrasound thermal therapy with the unparalleled imaging capabilities of MRI.

Our prototype has seamlessly integrated these two technologies into a system that provides an unmatched level of precision in the treatment of the whole prostate or targeted regions of disease within the prostate gland.

The company’s vision is to advance the pre-clinical and clinical development in all major global markets to appropriate regulatory compliance.

Profound Medical Inc is a
2008-2009 Life Science winner
in the annual OCRI Canada's Top 10 Competition.